CureVac
Sign in to saveAlso known as CureVac GmbH
thumb|Headquarters of CureVac in Tübingen CureVac is a biopharmaceutical company based in Tübingen, Germany that develops therapies based on messenger RNA (mRNA). With approximately 375 employees in 2018, it was founded in 2000 by Ingmar Hoerr, Steve Pascolo, Florian von der Mulbe, Günther Jung, and Hans-Georg Rammensee.
OverviewAI-generated
CureVac is a company and funder based in Tübingen, Germany. The organization was established in 2000 and maintains an active status. It currently employs 600 people.
Recent information indicates that CureVac is now part of the BioNTech Group.
Synthesized by Vinony from 12 facts across 3 sources: Wikidata, Firecrawl, ROR. Generated from structured data (not the Wikipedia text) and checked against those facts — may still contain errors.
Key facts
- Company.name
- CureVac N.V.
- Company.logo
- CureVac-mit-Claim-RGB Logo.png
- Company.type
- Public
- Company.founders
- Ingmar HoerrSteve PascoloFlorian von der MuelbeGünther JungHans-Georg Rammensee
- Company.location
- Tübingen, Germany
- Company.num_employees
- < 700
- Company.key_people
- Franz-Werner Haas (CEO)Steve Pascolo (CSO)Florian von der Mulbe (COO)
- Company.industry
- Biotechnology
via Wikipedia infobox
Research organization · ROR
- Type
- Company, Funder
- Founded
- 2000
- Location
- Tübingen, Germany
- Status
- Active
GRID grid.476259.b · ISNI 0000 0004 5345 4022
Wikidata facts
- Instance of
- public company
- Country
- Germany
- Headquarters
- Tübingen
- Owned by
- KfW
- Employees
- 600
- Stock exchange
- Nasdaq
- Legal form
- Aktiengesellschaft
- Official website
- www.curevac.com
- Image
- CureVac Hauptsitz in Tübingen.jpg
Show 5 more facts
- inception
- 2000-01-01
- investor
- Dietmar Hopp
- estimated value
- 1200000000
- social media followers
- 20613
- Commons category
- CureVac
Sources (9)
via Wikidata · CC0
~1 min read
Encyclopedic overview
8 sectionsContents
- History
- Research collaborations
- Investment
- Reports of Trump administration overtures
- Acquisition
- COVID-19 vaccine candidate
- References
- External links
BioNTech successfully closed the acquisition of CureVac. With this, CureVac is now part of the BioNTech Group (Nasdaq: BNTX), a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. Please visit [www.biontech.com](https://www.biontech.com/) [career.curevac.com](https://career.curevac.com/)
Excerpted from Wikipedia’s “CureVac” article, available under the CC BY-SA 4.0 licence.